Advanced Therapies (AT) have delivered remarkable clinical successes in recent years, transforming the treatment landscape for previously untreatable diseases. However, their broader impact remains constrained by significant challenges including manufacturability, scalability, consistency, and cost. This roundtable will explore the AT revolution, with a focus on cell and gene therapies and the critical role of viral vector CDMOs in enabling their commercialization. The discussion will bring together expert perspectives on how Switzerland can leverage its strengths to accelerate the translation of innovation into commercially viable therapies.
Tuesday, May 5, 12:10 - 12:40, room Rio, level 2
DINAMIQS, headquartered in Schlieren/ Zurich, is a pure-play viral vector CDMO focused on adeno-associated virus (AAV) and lentiviral vectors (LVV) for cell and gene therapies. The company provides integrated USP and DSP development, including genome engineering and process optimization for novel capsids, with rapid scale-up to clinical GMP production in 7–9 months. Its scalable, suspension-based platform up to 1000L utilizes single-use, fully closed systems to ensure reproducibility and commercial readiness. Comprehensive in-house analytical development, QC, and stability testing support seamless progression from pre- to clinical stages.
